Navigation Links
Amgen Announces Evolocumab (AMG 145) Results From First 52-Week Study Of A PCSK9 Inhibitor To Reduce LDL Cholesterol
Date:11/19/2013

ve dosing options of evolocumab in a range of at-risk patient populations."

OSLER is an ongoing open-label extension study evaluating the long-term safety and efficacy of evolocumab in patients with high cholesterol. In the first year, patients were randomized 2:1 to receive evolocumab and SOC or SOC alone.

"Many patients with high cholesterol struggle to adequately reduce their LDL-C, a significant contributor to cardiovascular disease," said Michael Koren, M.D., of the Jacksonville Center for Clinical Research. "The results from the OSLER study are encouraging as evolocumab may offer a potential treatment option for patients who cannot control their cholesterol levels."

Adverse events occurred in 81.4 percent of patients treated with evolocumab and SOC and in 73.1 percent of the SOC group. The five most common AEs in the evolocumab and SOC group compared to the SOC group were nasopharyngitis (12.2 percent vs. 9.8 percent), upper respiratory tract infections (7.7 percent vs. 7.6 percent), influenza (7.1 percent vs. 5.2 percent), arthralgia (6.9 percent vs. 4.3 percent), and back pain (6.5 percent vs. 5.4 percent). Other AEs that were reported included muscle-related events (9.2 percent vs. 9.8 percent), elevated liver function tests (1.8 percent vs. 1.6 percent), and elevated creatine kinase (1.0 percent vs. 1.9 percent) for patients treated with evolocumab and SOC compared to SOC alone, respectively. Serious AEs occurred in 7.1 percent of patients treated with evolocumab and SOC and 6.3 percent of the SOC group.

In the OSLER clinical trial, subcutaneous monthly treatment with evolocumab in combination with SOC resulted in a significant LDL-C decrease versus SOC alone in patients who previously completed one of four 12-week Phase 2 studies of evolocumab. After 52 weeks of treatment, patients who first received evolocumab in the OSLER study experienced an average of 52 percent reduction in LDL-C, as
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
2. Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013
3. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
4. Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
5. Amgen And ShanghaiTech University Announce Plans For Amgen China R&D Center To Open On ShanghaiTech Campus
6. Amgen And Servier Complete Product Collaboration Transaction
7. Amgen Announces 2013 Third Quarter Dividend
8. Technical Briefing: Amgen, PDL BioPharma, Questcor Pharma, and BioCryst Pharma
9. Amgen And Servier Announce Product Collaboration
10. Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations
11. Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015  Discovery Laboratories, Inc. (Nasdaq: DSCO ... second $1.0M tranche under a previously awarded Phase ... at up to $3.0 million to support continued ... a potential medical countermeasure to mitigate acute and ... an initial $1.0 million under this grant in ...
(Date:7/29/2015)... July 30, 2015 Sanofi, ... publie ses résultats pour le premier semestre 2015. ... les résultats. Visionner l,interview vidéo et ... Au sommaire de l,interview :  ... Moteurs de croissance - Diabète ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... the Company,s Chief Financial Officer has resigned.  The Company ... Financial Officer who retired in December 2014, as full ... a permanent successor.     Andy Ashworth ... and ensure a smooth transition.  Andy was the Company,s ...
(Date:7/29/2015)... July 29, 2015 ... the addition of the "Global Biosimilars Market, ... The Global Biosimilars Market, 2015 - ... rapidly growing biosimilars market. With the blockbuster biologics ... minimize costs, biosimilars are being viewed as viable ...
Breaking Biology Technology:Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3
... Integrated Global Services, CAMBRIDGE, Mass., April 1, ... a new name, Abt Bio-Pharma Solutions, Inc., a,wholly ... will continue to,provide custom strategic, research and communication ... industries,utilizing a team approach that blends decades of ...
... Derma Sciences,Inc (OTC Bulletin Board: DSCI), a provider of ... $34.1 million, an increase of 22 percent,over the $27.9 ... 34,percent, but due primarily to the costs of bringing ... marketing and sales staffs, the,Company reported a loss of ...
... 1, 2008 Champions,Biotechnology, Inc. (OTC Bulletin Board: ... preclinical platforms and tumor specific data to,enhance the ... of new,Board of Directors members and the formation ... expand its operations., Abba David Poliakoff and ...
Cached Biology Technology:Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc. 2Derma Sciences Reports Fourth Quarter Year-End Results for 2007 2Derma Sciences Reports Fourth Quarter Year-End Results for 2007 3Derma Sciences Reports Fourth Quarter Year-End Results for 2007 4Derma Sciences Reports Fourth Quarter Year-End Results for 2007 5Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team 2Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team 3Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team 4Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team 5Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team 6Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team 7Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team 8
(Date:6/30/2015)... YORK , June 30, 2015 To bolster ... security provider HYPR Corp. announced today the addition of two ... will serve as board advisor and David Raviv ... the team underscore HYPR Corp.,s commitment to providing the most ... Dimitri Sirota co-founded Layer 7 Technologies, a provider ...
(Date:6/25/2015)... DALLAS , June 25, 2015 ... report "Fingerprint Sensors Market by Type (Swipe & Area), Technology, ... (Mobile, Government, Healthcare, Commercial Security & Others) & ... published by marketsandmarkets, the said market is expected ... CAGR of 17.1%. Browse 76 ...
(Date:6/24/2015)... 2015 This report provides market analysis of ... years. It contains an analysis of the drivers, challenges, ... impact from the short, medium, and long term perspective ... market, and technology trends that currently, prevail in the ... authorities to efficiently manage the increasing marine traffic and ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... non-coding RNAs are small molecules that help control ... they have emerged as disease biomarkers. miRNA profiles ... cancers of unknown primary origin, determine prognosis, monitor ... tractable, diagnostic methods for monitoring miRNA expression in ...
... scientists have focused among other factors on drugs ... is the accumulation of A-beta that causes the known plaques ... formation of A-beta is APP. Alessia Soldano and Bassem Hassan ... APPL the fruit-fly version of APP in the ...
... Automated conserved noncoding sequence (CNS) discovery reveals ... Within the genome of each species, there are thousands ... and sequence over millions of years, but do not code ... conserved noncoding sequences (CNSs), are known to regulate the expression ...
Cached Biology News:A new strategy required in the search for Alzheimer's drugs? 2Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3
Puromycin resistance gene (pac), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
...
... is designed to allow neomycin/kanamycin selection ... The loxP-PGK-gb2-neo-loxP template encodes the neomycin/kanamycin ... promoter (gb2) for expression of kanamycin ... promoter (PGK) for expression of neomycin ...
... These precision 5mm diameter, 7 inch long PYREX ... for compatibility with ground joints, valves, and vacuum ... spectrometers running from 300 to 500MHz. They have ... I.D. of 4.20 + 0.013-0.000mm. These NMR tubes ...
Biology Products: